This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Ms. Mitrany has been serving as SVP Head of Teva’s corporate economic department since 2012, with global responsibility for Teva’s business planning and analysis.
Prior to that Ms. Mitrany held various positions in Teva, including CFO of specialty R&D, and CFO and FP&A of the global branded business.
Ms. Mitrany joined Teva in 1995 as a financial analyst of Copaxone – the first innovative product of Teva for the treatment of multiple sclerosis.
Ms. Mitrany received her BA in Economics and MBA in Finance, both from Tel-Aviv University.
With over 20 years of experience in finance, M&A and business operations, primarily in the pharmaceutical industries, Ms. Mitrany provides broad and experienced knowledge of the global pharmaceutical business and industry.